Healthcare / Pharmaceutical RetailersNZSE
$2.04
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $40.2M · quality 76.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$294M
P/E
17.0x
↓EV/EBITDA
8.0x
↓ROE
9.6%
↑Gross Margin
57.4%
↑Debt/Equity
0.81
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.7%
FCF CAGR
-8.8%
FCF margin
8.9%
FCF / Net income
2.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $523.8M · net income $16.0M · FCF $46.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $523.8M | $523.8M | $503.8M | $492.6M | $666.6M |
| Net Income | $16.0M | $16.0M | $11.8M | $45.2M | $24.6M |
| EBITDA | $50.3M | $50.3M | $45.5M | $50.6M | $73.6M |
| EPS | 0.11 | 0.11 | 0.08 | 0.31 | 0.17 |
| Gross Margin | 57.4% | 57.4% | 57.4% | 56.9% | 68.5% |
| Operating Margin | 7.1% | 7.1% | 6.2% | 6.5% | 7.4% |
| Net Margin | 3.1% | 3.1% | 2.3% | 9.2% | 3.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.81 | 0.81 | 0.94 | 0.64 | 0.74 |
| Current Ratio | 0.98 | 0.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $46.8M | $46.8M | $38.6M | $40.2M | $61.7M |
| Returns | |||||
| ROE | 9.6% | 9.6% | 7.6% | 23.6% | 15.4% |
| Valuation | |||||
| P/E | 17.00 | 17.00 | 12.47 | 5.34 | 8.07 |
| EV/EBITDA | 8.00 | 8.00 | 5.89 | 6.05 | 3.67 |
| P/B | 1.76 | 1.76 | 0.95 | 1.26 | 1.24 |
| Growth & Yield | |||||
| Revenue Growth | 4.0% | 4.0% | 2.3% | -26.1% | — |
| EPS Growth | 35.7% | 35.7% | -74.0% | 84.0% | — |
| Dividend Yield | 5.4% | 5.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.7%
EPS terminal req.
$0.18
Spread vs growth
18.0%
5Y implied EPS CAGR
14.6%
EPS terminal req.
$0.22
Spread vs growth
21.1%
10Y implied EPS CAGR
12.3%
EPS terminal req.
$0.35
Spread vs growth
23.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+157.2%
Start / end P/E
9.9x → 18.4x
EPS bridge
0.08 → 0.11
Residual
+30.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.